(Oncodesign) Novel PSMA+ and FAP+ mouse models to support the development of novel molecular radiotherapy agents

New radiotherapy development with genO-BRGSF

May 21, 2025

Abstract

  • Robust preclinical models are required for the evaluation of novel PSMA-overexpressing mouse models molecular radiotherapies (MRT):
    • accuratelymimicking human tumor microenvironments
    • Expressing optimal levels of target proteins.
  • Tow biomarkers of interest in the field of MRT and Oncology are:

1. Fibroblast activation protein (FAP): Minimally expressed in regular tissues, upregulated in cancer-associated fibroblasts within the tumor microenvironment.

2. Prostate-specific membrane antigen (PSMA): overexpressed in most prostate cancers.

  • Oncodesign Services already had PSMA-overexpressing models available, but only on Balb/c Nude mice. This strain is radiosensitve due to a mutation and has become unavailable for purchase in the recent months.
  • Furthermore, inherently expressing FAP models are available, but have minimal FAP-expression.
  • To close the gap in our catalogue, Oncodesign Services has recently developed novel FAP and PSMA-overexpressing models in nonradiosensitve mouse strains.

Related products

Catalogue product

genO‑BRGSF

Compared to NOD-SCID and NSG, the genO‑BRGSF mouse represents the most adapted animal model to study and predict human immune responses in vivo.

Customized product

No items found.
Related posters
No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe